Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial

Journal of Diabetes Investigation

Volumn 10, Issue 4, 2019, Pages 1012-1021

  Inoue, Hideka ^a   Morino, Katsutaro ^a   Ugi, Satoshi ^a   Tanaka Mizuno, Sachiko ^a   Fuse, Keiko ^a   Miyazawa, Itsuko ^a   Kondo, Keiko ^a   Sato, Daisuke ^a   Ohashi, Natsuko ^a   Ida, Shogo ^a   Sekine, Osamu ^a   Yoshimura, Masahiro ^a   Murata, Kiyoshi ^a   Miura, Katsuyuki ^a   Arima, Hisatomi ^b   Maegawa, Hiroshi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

Bodyweight; Sodium glucose cotransporter 2 inhibitor; Treatment drug

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSIDE; THIOPHENE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ARM; ARTICLE; BIOELECTRICAL IMPEDANCE ANALYSIS; BODY COMPOSITION; BODY MASS; BODY WEIGHT LOSS; BONE MINERAL; CONTROLLED STUDY; DIABETIC PATIENT; DIETARY INTAKE; DRUG DOSE REDUCTION; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY BALANCE; FAT MASS; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IMPEDANCE; INSULIN TREATMENT; JAPANESE (PEOPLE); LOWER LIMB; MALE; MORNING DOSAGE; MUSCLE MASS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRUNK; ADIPOSE TISSUE; BODY WEIGHT; COMBINATION DRUG THERAPY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SKELETAL MUSCLE; YOUNG ADULT;

ADIPOSE TISSUE; ADULT; AGED; BIOMARKERS; BODY COMPOSITION; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PROGNOSIS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; THIOPHENES; YOUNG ADULT;

EID: 85064167450     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12985     Document Type: Article

References (27)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–853.
2. Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2011; 13: 1008–1019.
3. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med 2013; 159: 262–274.
4. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020–1031.
5. Hu X, Zhang L, Wang H, et al. Malnutrition-sarcopenia syndrome predicts mortality in hospitalized older patients. Sci Rep 2017; 7: 3171.
6. Rizzoli R, Reginster JY, Arnal JF, et al. Quality of life in sarcopenia and frailty. Calcif Tissue Int 2013; 93: 101–120.
7. Kim TN, Park MS, Yang SJ, et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: The Korean Sarcopenic Obesity Study (KSOS). Diabetes Care 2010; 33: 1497–1499.
8. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014; 16: 1016–1027.
9. Darin R, Patompong U, Jutarat S, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev 2017; 33: e2903.
10. Cai X, Ji L, Chen Y, et al. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: a meta-analysis. J Diabetes Investig 2017; 8: 510–517.
11. Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014; 16: 124–136.
12. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015; 38: 403–411.
13. Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014; 16: 159–169.
14. Yamamoto C, Miyoshi H, Ono K, et al. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J 2016; 63: 589–596.
15. Kawata T, Iizuka T, Iemitsu K, et al. Ipragliflozin improves glycemic control and decreases body fat in patients with type 2 diabetes mellitus. J Clin Med Res 2017; 9: 586–595.
16. Seino T, Yabe D, Sasaki T, et al. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: a 52-week, open-label, single-arm study. J Diabetes Investig 2018; 9: 332–340.
17. Osonoi T, Nakamoto S, Saito M, et al. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: a subgroup analysis based on patient characteristics. J Diabetes Investig 2018; 9: 341–353.
18. Carey DG, Pliego GJ, Raymond RL. Body composition and metabolic changes following bariatric surgery: effects on fat mass, lean mass and basal metabolic rate: six months to one-year follow-up. Obes Surg 2006; 16: 1602–1608.
19. Gomez-Arbelaez D, Bellido D, Castro AI, et al. Body composition changes after very-low-calorie ketogenic diet in obesity evaluated by 3 standardized methods. J Clin Endocrinol Metab 2017; 102: 488–498.
20. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009; 11: 1163–1172.
21. Kim B, Tsujimoto T, So R, et al. Weight reduction does not induce an undesirable decrease in muscle mass, muscle strength, or physical performance in men with obesity: a pilot study. J Exerc Nutrition Biochem 2017; 21: 37–44.
22. Johnson MA, Polgar J, Weightman D, et al. Data on the distribution of fibre types in thirty-six human muscles: an autopsy study. J Neurol Sci 1973; 18: 111–129.
23. Albers P, Pedersen A, Birk J, et al. Human muscle fiber type-specific insulin signaling: impact of obesity and type 2 diabetes. Diabetes 2015; 64: 485–497.
24. Nomiyama T, Shimono D, Horikawa T, et al. Efficacy and safety of sodium–glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION). Endocr J 2018; 65: 859–867.
25. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117–2128.
26. Achamrah N, Colange G, Delay J, et al. Comparison of body composition assessment by DXA and BIA according to the body mass index: a retrospective study on 3655 measures. PLoS ONE 2018; 13: e0200465.
27. Buckinx F, Reginster J-Y, Dardenne N, et al. Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptiometry: a cross-sectional study. BMC Musculoskelet Disord 2015; 16: 60.